May 11th 2018
Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.
May 10th 2018
Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.
April 25th 2018
Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.
Michael J. Mauro, MD, discusses updates presented at the 2017 ASH Annual Meeting and the advances that are on the horizon for patients with chronic myeloid leukemia.
April 23rd 2018
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.
April 20th 2018
Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.
April 19th 2018
Lindsay West, MD, discusses the relationship between low-fat or high-fat diets and endometrial cancer and how these can be investigated further.
April 18th 2018
Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.
Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD.
April 13th 2018
Thomas E. Stinchcombe, MD, discussea existing and emerging first-line regimens coming through the pipeline for the treatment of patients with non–small cell lung cancer.
Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.
April 12th 2018
The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.
There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.
April 10th 2018
The incidence of neuroendocrine tumors has increased 5-fold over the past 30 years, making it the second most prevalent diagnosis in gastrointestinal (GI) malignancies.
April 9th 2018
Mark D. Pegram, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer.
April 6th 2018
Heather Han, MD, discusses emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.
April 5th 2018
Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.
March 30th 2018
Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.
Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.